HPTN Studies

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-network review process that ensures compliance with current ethical guidelines and regulatory procedures.

Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites. The CORE Protocol Contact can provide additional information and materials.

Recent Publications

Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP . Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis [HPTN 083]. Ann Intern Med. 2022, 175: 479-489
Mohammed Limbada, David Macleod, Vasty Situmbeko, Ellen Muhau, Osborn Shibwela, Bwalya Chiti, Sian Floyd, Albertus J Schaap, Richard Hayes, Sarah Fidler, Helen Ayles . Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial. Lancet HIV. 2021, 9: E13-E23
Mark A. Marzinke, Beatriz Grinsztejn, Jessica M. Fogel, Estelle Piwowar-Manning, Maoji Li, Lei Weng, Marybeth McCauley, Vanessa Cummings, Shahnaz Ahmed, Casey D. Haines, Lane R. Bushman, Christos Petropoulos, Deborah Persaud, Adeola Adeyeye, Ryan Kofron, Alex Rinehart, Marty St Clair, James F. Rooney, Daniel Pryluka, Lara Coelho, Aditya Gaur, Keren Middelkoop, Nittaya Phanuphak, Myron S. Cohen, Craig W. Hendrix, Peter Anderson, Brett Hanscom, Deborah Donnell, Raphael J. Landovitz, Susan H. Eshleman, Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, McCauley M, Cummings V, Ahmed S, Haines CD, Bushman LR, Petropoulos C, Persaud D, Adeyeye A, Kofron R, Rinehart A, St Clair M, Rooney JF, Pryluka D, Coelho L, Gaur A, Middelkoop K, Phanuphak N, Cohen MS, Hendrix CW, Anderson P, Hanscom B, Donnell D, Landovitz RJ, Eshleman SH . Characterization of Human Immunodeficiency Virus
(HIV) Infection in Cisgender Men and Transgender
Women Who Have Sex With Men Receiving Injectable
Cabotegravir for HIV Prevention: HPTN 083
. J Infect Dis. 2021, 224: 1581-1592
Jeremy Sugarman, Deborah J Donnell, Brett Hanscom, Marybeth McCauley, Beatriz Grinsztejn, Raphael J Landovitz, Sugarman J, Donnell DJ, Hanscom B, McCauley M, Grinsztejn B, Landovitz RJ . Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. Lancet HIV. 2021, 8: e723-e728

Scholars Program

The HIV Prevention Trials Network (HPTN) is proud to offer two scholarship programs for early-career investigators funded through a supplement from the National Institute of Allergy and Infectious Diseases (NIAID). The HPTN Scholars Program now includes two components: a domestic (U.S.) program and an international program. Both programs seek to increase opportunities for scientists from groups under-represented in HIV prevention research.

In the domestic program, successful applicants will be Investigators who have received their terminal degree (MD, Phd, etc). For the international version, current MD, PhD, and MBChB students may apply, along with individuals having already graduated with their terminal degree. In both programs, applicants should desire to work with a mentor scientist in the Network to complete a research project based upon an existing HPTN research study.

Learn more about the Scholars Program